Scarica l'app Stockscreener
6.29
5.70%
-0.38
Dopo l'orario di chiusura:
6.40
0.11
+1.75%
Precedente Chiudi:
$6.67
Aprire:
$6.45
Volume 24 ore:
1.09M
Relative Volume:
1.22
Capitalizzazione di mercato:
$320.51M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.1958
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
-19.67%
1M Prestazione:
+6.25%
6M Prestazione:
-35.29%
1 anno Prestazione:
-67.15%
Intervallo 1D:
$6.26
$6.545
Intervallo di 1 settimana:
$6.26
$7.46
Portata 52W:
$5.66
$19.88
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
6.29 | 320.51M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com
Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia
Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India
5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks
REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena
Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada
REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com
Regenxbio stock target raised to $29 at Raymond James - Investing.com India
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga
Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener
REGENXBIO reports promising gene therapy trial results - Investing.com India
REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq
Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India
Regenxbio completes its BLA filing for first potential gene therapy for MPS II - The Pharma Letter
REGENXBIO Earnings Call Highlights Strategic Progress - TipRanks
Earnings call transcript: Regenxbio Q4 2024 beats EPS forecast, stock surges - Investing.com Australia
Stifel maintains Buy on Regenxbio stock, $40 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Regenxbio stock, $40 target - Investing.com India
A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts - Benzinga
Regenxbio Inc earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Canada Finance
REGENXBIO Reports Progress in Gene Therapy Pipeline - TipRanks
Regenxbio Q4 License & Royalty Revenue USD 21.214 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regenxbio Inc (RGNX) Q4 2024 Earnings: EPS Beats Estimates at -$1.01, Revenue Misses at $21.2 Million - GuruFocus.com
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Regenxbio: Q4 Earnings Snapshot - San Antonio Express-News
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):